Dr Alexander Wilke

Senior Director Global Market Access & Pricing | Neuroeconomist | Neuro Public Health Expert

Greater Munich Metropolitan Area

About

Experience

  • Norgine (3 yrs 7 mos)
    • Senior Director Global Market Access & Pricing
      Dec 2022 - Present · 3 yrs 7 mos

    • Director of Market Access
      Dec 2022 - Present · 3 yrs 7 mos

      (Member of Management Team) Tasks • Leading global and local Market Access Team (12) • Development of HEOR / Value strategy (e.g., Market Access Value Studies, Multi criteria decision analysis / Cost – Benefit Studies, Indirect treatment comparisons; MAIC`s, MCDI`s; Indication specific payer uncertainty value coefficient decision tools) • Global Management and Development of HTA and reimbursement strategies for the main Market countries • Development of special market access entrée agreements and other individual contract forms for extra budgetary reimbursement • Development of International and National Pricing Strategies • Development and implementation of patient access projects and chronic care management programs across Europe • Developing and execution of patient advocacy and health policy activities and strategies in the Norgine countries worldwide • Development of healthcare solutions and new health care Pathways in cooperation with the relevant stakeholder • Development of Market Access related Due Diligence and Market Access related clinical Study Analysis • Development of negotiation strategies and building of pricing rationales

  • Scientific Director and CEO at Institute for evidence based market access, health system management and strategic reimbursement
    Feb 2017 - Present · 9 yrs 5 mos

    The institute implements in cooperation with payers and governmental authorities, innovation into the health system and to the patient. Medical products, treatments , diagnostics and other innovations are our business. We are helping companies and payer to create optimal win - win situations. As passionate Market Access and Patient Accesss experts we are working on scientific and evidence based solutions and strategies for companies. (Scientific based contracting, AMNOG processes, value related innovative HEOR methods, and value based pricing and reimbursement barrier management are some key words which describing our daily business.)

  • Scientific team lead (Neuromodulation of cerebral structures) at Human Brain Project
    Feb 2020 - Present · 6 yrs 5 mos

  • Chief Executive Officer at Institute for evidence based health care management and patient access I.f.G.V.
    Jan 2013 - Present · 13 yrs 6 mos

    Tasks Development of HEOR studies for health politicians, governmental authorities and health insurance companies Development of innovative Health care solutions and Patient Access pathways HEOR consulting and implementation of studies: - Health outcomes studies - Budget Impact Models - Payer Value Analysis - Patient Con Joint Analysis - Burden of Illness Studies - Health-and Pharma economic Studies - Indirect Treatment Comparisons /n MIAC and Meta-Analysis - Multi-criteria Decision Analysis with Neuroeconomic Approach Interface to the governmental authorities (GBA, BMG, GKV SV, IQWIG) Official advising member of the GBA “medical innovation and drug commission” Different consultant activities around the AMNOG process (dossier, market access related value analysis, negotiation scenarios) Reimbursement strategy / defense management and strategies for medical product and pharmaceutical companies. Development of AMNOG`s and medical product benefit assessments (24 AMNOG procedures; 15 GKV SV negotiations) Expert center for Neuroeconomic / Neuro Public Health & HEOR Member of the Human Brain Project; leading the medical task force for neuroplasticity & neuroeconomics

  • Ipsen Pharma GmbH (5 yrs 3 mos)
    • Director Market Access & Public Affairs (D-A-CH)
      Dec 2017 - Dec 2022 · 5 yrs 1 mo

    • Director of Market Access
      Oct 2017 - Nov 2022 · 5 yrs 2 mos

      (Member of Management Team Europe) Tasks • Leading the Market Access Team (12 employees) • Development of HEOR / Value strategy (e.g., Market Access Value Studies, Multi criteria decision analysis / Cost – Benefit Studies, Indirect treatment comparisons; MAIC`s, MCDI`s; Indication specific payer uncertainty value coefficient decision tools) • Implementation of AMNOG procedures and GKV SV negotiations. (personally experience 27 AMNOG procedures and 21 negotiation; 4 with arbitration board) • Development of special market access entrée agreements and other individual contract forms for extra budgetary reimbursement • Development and implementation of the scientific health policy Counselling approach at German parliament • Development and implementation of patient access projects and chronic care management programs • Responsible for Tender and Contract Management for DACH Region • Development of healthcare solutions and new health care Pathways in cooperation with the relevant stakeholder